Predictor factor of survival in advanced hepatocellular carcinoma treated with sorafenib ∼a multicenter study∼

Objective: To determine the predictor factor of survival after sorafenib therapy. Methods: The study assessed 314 patients with advanced HCC treated with sorafenib at 5 general hospitals in Kagawa Prefecture, Japan. Results: The study included 254 men and 60 women. Their mean age was 72.5 years, their mean height was 160.4 cm, and their mean weight was 58.6 kg. There were 43 patients with hepatitis B virus infection, 175 patients with hepatitis C virus infection, and 96 patients with other forms of liver disease. There were 295 patients with a history of treatment for HCC and 19 patients with no such history. The mean initial sorafenib dose was 391.7 ±159 mg. At the start of sorafenib therapy, 23.6% of patients had a Child-Pugh score other than A. The initial sorafenib dose was 800 mg in 9.2% of patients and 400 mg in 64.3%. Time to progression (TTP) was 129 days and median overall survival (m OS) was 392 days. The OS of patients with Child-Pugh A was significantly better than those with Child-Pugh B (P < 0.0001). The survival curves for Child-Pugh A-5 points and A-6 points were significantly different, with that of A-5 being better (P < 0.0001). A significant difference was observed between patients who exhibited HFS and those who did not, with the former exhibiting a better survival rate (P < 0.001). In addition, the survival rate of the patients who received post-progression treatment after sorafenib therapy was significantly better than that of the patients who did not (P < 0.001). Conclusion: In sorafenib therapy, the patients who exhibited hand-foot syndrome showed good overall survival.